Cocrystal Pharma Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $225KTTM through 30 Jun 2026
Net Income -$9.9MTTM through 30 Jun 2026
Free Cash Flow -$8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -1,047.1% |
| Net Margin | -1,021.8% |
Returns
-139.5%ROE
-118.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.66x
Net Debt-$4.7Mnet cash position
Cash & Equivalents$7M
Quality Metrics
Altman Z-Score-107.86
Piotroski F-Score2 / 9
FCF Margin-3,540.4%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2020: $2M
Diluted EPS-$0.75TTMFY2025: $-0.78
Dividend
No dividend
Capital Allocation
Capex Intensity5.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Antiviral Drug Development | $225K | View detailsThe company is focused on advancing its clinical pipeline, specifically CDI-988 for norovirus and CC-42344 for influenza. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.